The early detection of a cancer is a critical factor in its characterization, treatment, and eventual elimination. Many cancers, however, grow undetected because we do not have a sufficiently accurate or sensitive means to detect them. In recent years, advances in the detection of cancer-specific DNA in the blood—so-called cell-free DNA (cfDNA)—have given clinicians hope that liquid biopsies might provide a minimally invasive way to identify primary cancers much sooner and to alert doctors to relapse following treatment by identifying minimal residual disease. The development of successful screening methods will get us ever closer to the goal of precision oncology. Challenges still remain, however, including finding ways to detect low-frequency mutations in cfDNA and to identify other DNA aberrations, such as copy-number alterations, breaks, and methylation changes. This webinar will explore advances in early cancer screening, including recent successes and new methodologies for cfDNA detection and analysis.
During this webinar, the speakers will:
- Discuss the importance and clinical rationale for early cancer screening, providing examples from liver and pancreatic cancer
- Explain how liquid biopsies from blood and other fluids can provide a valuable complement to current standard-of-care tests such as mammograms and colonoscopies
- Discuss results from recent studies using some of the latest cfDNA detection methodologies
- Explore potential clinical applications for early cancer screening as we move toward individualized patient treatment.
This webinar will last for approximately 60 minutes.